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Abstract The aim of this study was to evaluate the participa-
tion of polymorphism at position C421A and mRNA expres-
sion of the ABCG2 gene in the development of peptic ulcers,
which is a very common and severe disease. ABCG2,
encoded by the ABCG2 gene, has been found inter alia in
the gastrointestinal tract, where it plays a protective role elim-
inating xenobiotics from cells into the extracellular environ-
ment. The materials for the study were biopsies of gastric
mucosa taken during a routine endoscopy. For genotyping
by polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) at position C421A, DNA was
isolated from 201 samples, while for the mRNA expression
level by real-time PCR, RNA was isolated from 60 patients.
The control group of healthy individuals consisted of 97 blood
donors. The dominant genotype in the group of peptic ulcer
patients and healthy individuals was homozygous CC. No
statistically significant differences between healthy individ-
uals and the whole group of peptic ulcer patients and, like-
wise, between the subgroups of peptic ulcer patients (infected
and uninfected withHelicobacter pylori) were found. ABCG2
expression relative to GAPDH expression was found in 38 of
the 60 gastric mucosa samples. The expression level of the
gene varies greatly among cases. The statistically significant
differences between the intensity (p=0.0375) of H. pylori in-
fection and ABCG2 gene expression have been shown. It was
observed that the more intense the infection, the higher the
level of ABCG2 expression.
Keywords ABCG2 . C421A . Expression .Helicobacter
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Introduction
Peptic ulcer (PU) is a disease with a high percentage of mor-
bidity. Due to its complications such as bleeding, pyloric ste-
nosis and life-threatening perforations occurring in 10–20 %
of patients, peptic ulcer diseases are a serious condition.
According to the Demographic Yearbook of Poland, in
2012, 1886 people died because of duodenal and gastric ulcer
in Poland (Dmochowska 2014; Malfertheiner et al. 2009;
Ramakrishnan and Salinas 2007; Szyca et al. 2012; Thorsen
et al. 2013).
The development of peptic ulcer may be influenced not
only by environmental factors, e.g. cigarette smoking, alcohol
consumption, diet high in salt, steroids and non-steroidal anti-
inflammatory drugs, Helicobacter pylori infection and stress,
but also a patient’s genetic predisposition (Schabowski 2002;
Thorsen et al. 2013). It concerns changes in the genes physi-
ologically involved in the protection of gastric mucosa.
One of the plausible genetic factors contributing to the
development of peptic ulcer disease could be changes in the
ABCG2 gene. It encodes protein named ABCG2 with 655
amino acids (previously BCRP, breast cancer resistance pro-
tein), which is a half-transporter belonging to the ABC trans-
porters superfamily. As for all proteins in this family, ABCG2
uses energy from ATP hydrolysis to transport substrates. The
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protein has been found inter alia in the brain, blood–brain
barrier, prostate, ovaries, testes, placenta, adrenal gland and
gastrointestinal tract, where it plays a protective role eliminat-
ing xenobiotics from cells into the extracellular environment.
In the digestive tract, ABCG2 is localised in the apical mem-
brane of cells, which confirms the hypothesis of its protective
role by limiting accumulation in cells/organs of harmful xe-
nobiotics. On the other hand, one loss of its function could
promote peptic ulcer development (Mao and Unadkat 2005;
Mo and Zhang 2012; Liu and Liu 2013).
The ABCG2 gene is highly polymorphic. So far, over 40
single nucleotide polymorphisms (SNPs) have been found
(Iida et al. 2002). SNPs may affect the level of mRNA expres-
sion, which leads to a change/loss of ABCG2 function. This
could result in the accumulation of xenobiotics in cells and,
thus, in the increased risk of peptic ulcer disease development.
One of such polymorphisms is the SNP substitution of C to T
at position 421. It is a non-synonymous polymorphism lead-
ing to a change of glutamine into lysine at position 141 in
protein (Q141K) (Cusatis et al. 2006). The ABCG2 gene poly-
morphism at position 421 is associated with a lower expres-
sion and a lower transport activity of encoded protein (Imai
et al. 2002; Kondo et al. 2004; Mizuarai et al. 2004).
Fehér et al. (2013) found a significantly increased suscep-
tibility to Alzheimer’s disease [odds ratio (OR)=1.741, 95 %
confidence interval (CI): 1.075–2.819, p=0.024) associated
with the ABCG2 C/C genotype when compared with the var-
iant allele containing genotypes CA and AA as the control
group. In pancreatic cancer, such a correlation was not found
(Pang et al. 2014).
The aim of this study was to evaluate the participation of
polymorphism at position C421A and the mRNA expression
level of the ABCG2 gene in the development of peptic ulcer.
To the best of our knowledge, this area has not been explored
so far.
Materials and methods
The materials for the study were biopsies of gastric mucosa
taken during endoscopy from patients with peptic ulcer diag-
nosed at the Department of Surgery, District Hospital,
Leczyca, Poland. The obtained samples were residual material
remaining after a routine diagnostics.
A small amount of biopsies material did not allow the si-
multaneous isolation of two nucleic acids (DNA and RNA)
from one sample. Therefore, in order to analyse both polymor-
phism at position C421A and mRNA expression, the group of
patients with peptic ulcer disease diagnosed at the same time
in the Department of Surgery, District Hospital, Leczyca,
Poland was divided into two investigated groups. The first
group consisted of 201 patients (129 females; 72 males; me-
dian age of the group: 53 years), from whom DNA was
isolated in order to genotype C421A of ABCG2 (investigated
group I). The other group consisted of 60 patients (34 females;
26 males; median age of the group: 60 years), from whom
RNA was isolated in order to assess the mRNA expression
level (investigated group II). Patients who were treated with
non-steroidal anti-inflammatory drugs were excluded from the
study.
The group of healthy individuals consisted of 97 blood
donors (58 females; 39 males; median age of the group: 33
years) from the local blood bank, and they geographically and
ethnically matched the group of patients with peptic ulcer.
Data concerning exposure to carcinogens in patients and
healthy individuals were not available. The investigation was
in accordance with the principles of the Declaration of
Helsinki, and was approved by the Ethical Committee of the
Medical University of Lodz (RNN/285/13/KE; RNN/195/13/
KE). All individuals included in the study gave informed
consent.
DNA and RNA isolation
DNA and RNA from biopsies of gastric mucosa collected
during a routine endoscopy were isolated according to the
Genomic DNA Mini and Total RNA Mini protocols, respec-
tively (A&A Biotechnology, Poland). The purity and concen-
tration of DNA and RNA samples were assessed spectropho-
tometrically. Until analysis, DNA and RNA samples had been
stored at −20 °C and −76 °C, respectively.
Genotyping of C421A
PCR
For the studied polymorphism, polymerase chain reaction
(PCR) was performed in accordance with the AccuTaq™
LA DNA Polymerase Kit protocol (Sigma Aldrich,
Germany). The mixture for PCR consisted of 10× AccuTaq
buffer, 1.5 mM of MgCl2, 0.5 μM of each primer (C421A F
5 ′-ATGTTGTGATGGGCACTCTG-3 ′; C421A R 5 ′-
TGCTGATCATGATGCTTTCAG-3′), 0.2 mM of each
dNTP, 0.5U of AccuTaq LA DNA Polymerase, 50 ng of
DNA template and distilled water to a final volume of
20 μL. In every experiment, a negative control was included.
Products of the PCR reactions were assessed by electrophore-
sis in 2 % agarose gel. Reaction products for the investigated
SNP had a size of 184 bp.
RFLP
Genotyping of C421Awas performed by restriction fragment
length polymorphism (RFLP). Amplified DNA fragments for
the SNP on position C421A were digested by MseI (New
England Biolabs, USA) for 16 h at 30 °C. Genotypes were
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identified by electrophoresis of amplified DNA fragments af-
ter digestion by restriction enzyme (two bands of 84 and
100 bp for genotype CC; three bands of 36, 64 and 84 bp
for genotype AA; four bands of 36, 64, 84 and 100 bp for
genotype CA).
Expression of ABCG2 mRNA
Reverse transcription
A total cellular RNA was transcribed into complementary
DNA (cDNA) in accordance with the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, USA). The
final concentration of RNA in the reaction mixture was
0.01 μg/μL. Synthesised cDNA was stored at −20 °C until
analysis. As a reference gene, GAPDH was used. Only the
samples which showed the presence of PCR product for the
GAPDH gene were included in the analysis.
PCR
For qualitative analysis of the mRNA expression of the refer-
ence gene GAPDH, a PCR assay was performed in accor-
dance with the AccuTaq™ LA DNA Polymerase Kit protocol
(Sigma Aldrich, Germany). The mixture for PCR consisted of
10× AccuTaq buffer, 1 mM of MgCl2, 0.5 μM of each primer
(GAPDH gene: F 5′-TGGTATCGTGGAAGGACTCAT
GAC-3′, R 5′-ATGCCAGTGAGCTTCCCGTTCAGC-3′),
0.2 mM of each dNTP, 0.5U of AccuTaq LA DNA
Polymerase, 0.2 μg of cDNA template and distilled water to
a final volume of 20 μL. In every experiment, a negative
control was included. Products of the PCR reactions were
assessed by electrophoresis in 2 % agarose gel. The reaction
product for GAPDH had a size of 257 bp.
Real-time PCR
Quantification assessment of ABCG2 (investigated gene) and
GAPDH (reference gene) mRNAwas performed by real-time
PCR using a Rotor-Gene™ 6000 (Corbett Research,
Germany), according to the KAPA SYBR® FAST qPCR Kit
Master Mix (2X) Universal protocol (Kapa Biosystems,
USA). The reaction mixture for both genes consisted of
10 μL KAPA SYBR FAST qPCR Master Mix (2X), 0.4 μL
of each primer (ABCG2 gene: F 5′-ATGTCAACTCC
TCCTTCTAC-3′; R 5′-AATGATCTGAGCTATAGAGGC-
3 ′ ; GAPDH g e n e : F 5 ′ - TGGTATCGTGGAA
GGACTCATGAC-3′, R 5′-ATGCCAGTGAGCTTCCC
GTTCAGC-3′), 1.5 μL of cDNA and distilled water up to a
final volume of 20 μL. The reactions for ABCG2 andGAPDH
were carried out in separate tubes. Samples were tested in
triplicate, and the mean of the obtained Ct values for both
ABCG2 and GAPDH was calculated. In each experiment, a
negative control, also tested in triplicate, was included. For
estimation of the kinetic PCR reaction efficiency, the standard
curves for both genes, by four serial 10-fold dilutions of a
quantified PCR product (obtained with the same primers as
those used in the quantification mRNA analysis), were con-
structed. The efficiencies were calculated from the slopes of
the standard curves according to the equation E=10[−1/slope]−
1. Because the efficiencies for both genes were different
(ABCG2 122 %;GAPDH 107 %), the Pfaffl method was used
to calculate relative changes in gene expression (Livak and
Schmittgen 2001; Tyburski et al. 2008). The mean Ct values
for the ABCG2 andGAPDH genes for all investigated samples
were utilised as calibrators.
Statistical analysis
All statistical analyses were performed using STATISTICA 10
(StatSoft, Inc., 2011). The χ2 test, χ2 test with Yates’ correc-
tion and V2 test were applied to evaluate conformity between
the observed and expected genotype frequencies according to
the Hardy–Weinberg rule and to determine the significance of
differences in allele and genotype frequencies between pa-
tients and controls and between subgroups of patients. The
collected quantitative data were tested to check for conformity
with a normal distribution on the basis of the Shapiro–Wilk
test. Because of the lack of normality of ABCG2 expression
values, decimal logarithm of the expression level was used for
statistical analysis. Student’s t-test and analysis of variance
(ANOVA) were applied to assess the differences in the mean
values of the ABCG2 expression between the subgroups of




All 201 biopsy specimen of gastric mucosa (peptic ulcer pa-
tients; investigated group I) and 97 blood samples (healthy
individuals) for the SNP at position C421A of the ABCG2
gene were successfully analysed. All genotypes for the inves-
tigated polymorphism in both peptic ulcer patients and healthy
individuals were in Hardy–Weinberg equilibrium.
Firstly, genotype and allele frequencies for the polymor-
phism at position C421A between peptic ulcer patients (inves-
tigated group I) and healthy individuals were compared
(Table 1). For both genotype and allele of the studied SNP,
no statistically significant differences between peptic ulcer
patients and healthy individuals were found (p=0.7845 and
0.9370, respectively). The dominant genotype in both groups
was homozygous CC (97.5 % for peptic ulcer and 97.9 % for
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healthy individuals), whereas genotype AA occurred only in
the group of patients with peptic ulcer (0.5 %).
Secondly, on the basis of the results of rapid urease tests,
the group of peptic ulcer patients were divided into two sub-
groups: patients infected with H. pylori and patients uninfect-
ed with this bacterium. The frequency of genotypes and alleles
of the SNP C421A for these two subgroups was compared.
No statistically significant differences for the studied poly-
morphism were observed (p=0.3591 and 0.2127, respective-
ly). Nevertheless, it is noteworthy that allele A occurred more
frequently in the subgroup of patients uninfected with
H. pylori than in the infected subgroup (2.5 % and 0.5 %,
respectively). The results are shown in Table 2.
In the last step of the analysis, the subgroups of patients
infected and uninfected with H. pylori were divided further
according to gender. First, a comparison of the incidence of
genotype and allele of polymorphism C421A between the
subgroup of infected women and a subgroup of women not
infected with H. pylori was conducted. No statistically signif-
icant differences were found (p=0.3524 and 0.2127, respec-
tively). However, allele A occurred more frequently in the
subgroup of uninfected women than in the subgroup of wom-
en infected withH. pylori. This observation was similar to the
results obtained in the whole subgroup of patients uninfected
with this bacterium. On the other hand, among men, no geno-
type AA was found. Therefore, no analogous analysis was
possible.
Expression of mRNA ABCG2
Initially, a qualitative analysis of the GAPDH gene was per-
formed to check the reverse transcription of the procedure. In
all tested samples, the expression of GAPDH was present.
ABCG2 expression was found in 38 of the 60 gastric mucosa
samples. There were no statistical differences between gender,
age and presence of the investigated gene expression
(Table 3). There was also no correlation between the presence
ofH. pylori infection and the presence of gene expression, but
in a more intensive infection, ABCG2 expression appeared
more frequently (p=0.0324, Table 3).
The expression level of ABCG2 relative to GAPDH varies
greatly among cases. It ranged from −1.64 to 1.75, with a
mean value of −0.13 (standard deviation 0.77). There was
no association between ABCG2 expression level and the pa-
tient’s gender (p=0.4957). Also, no connection between the
level and patient’s age was stated (p=0.5329, Table 4). No
difference in the expression level was also stated when it
Table 1 Comparison of C421A
ABCG2 allele and genotype
frequencies between peptic ulcer
(investigated group I) and healthy
individuals
Peptic ulcer cases, n=201 Healthy individuals, n=97 p-Value
CC 196 (97.5 %) 95 (97.9 %) 0.7845a
CA 4 (2.0 %) 2 (2.1 %)
AA 1 (0.5 %) 0 (0.0 %)
C 396 (98.5 %) 192 (99.1 %) 0.9370b
A 6 (1.5 %) 2 (1.0 %)
HWE: p 0.4960a 0.6134b
aχ2 test
bχ2 test with Yates’ correction
Table 2 Comparison of C421A ABCG2 allele and genotype
frequencies between the subgroup of patients infected with
Helicobacter pylori and the subgroup of patients uninfected with
H. pylori
All peptic ulcer cases p-Value
Infected, n=101 Uninfected, n=100
CC 100 (99.0 %) 96 (96.0 %) 0.3591a
CA or AA 1 (1.0 %) 4 (4.0 %)
C 201 (99.5 %) 195 (97.5 %) 0.2127a
A 1 (0.5 %) 5 (2.5 %)
aχ2 test with Yates’ correction
Table 3 Presence of ABCG2 expression according to gender, age,
presence and intensity of H. pylori infection
Feature ABCG2 expression p-Value
Absent Present
Gender 0.7749a
Female 13 (59.1 %) 21 (55.3 %)
Male 9 (40.9 %) 17 (44.7 %)
Age 0.7749a
<60 years 9 (40.9 %) 17 (44.7 %)
>60 years 13 (59.1 %) 21 (55.3 %)
H. pylori infection 0.1608a
Absent 11 (50.0 %) 26 (68.4 %)
Present 11 (50.0 %) 12 (31.6 %)
H. pylori infection intensity
Low 9 (81.8 %) 5 (41.7 %) 0.0324b
Medium 0 (0.0 %) 4 (33.3 %)
High 2 (18.2 %) 3 (25.0 %)
aV2 test
bχ2 test
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was compared between patients <60 and >60 years old. There
was no significant connection between the presence of
H. pylori infection and the expression level of ABCG2 (p=
0.2864, Table 4). In the H. pylori-infected patients divided
into three subgroups according the infection intensity, the ex-
pression level of the investigated gene differed significantly
between the subgroups (p=0.0375, Table 4). Themore intense
the infection, the higher the level of ABCG2 expression was
observed. The post-hoc analysis showed that there was a sig-
nificant difference in the expression level between the sub-
groups of low and high intensity of infection (p=0.0306,
Fig. 1).
Discussion
ABCG2was described for the first time in tumour cells, where
it produced a significant resistance to chemotherapeutic agents
(Doyle et al. 1998). The transporter on cells weakens access of
drugs to the cellular target and, thereby, contributes to a re-
duction in the efficacy of the applied therapy. As ABCG2 has
a low substrate specificity, it might contribute to the resistance
to structurally diverse anti-cancer drugs, a phenomenon called
multidrug resistance (MDR) (Gottesman et al. 2002).
However, ABCG2 is present not only in tumour cells, and
its function in the development of MDR is a manifestation
of the physiological role of this protein.
Protein product of the ABCG2 gene is located in many
normal tissues, including the gastrointestinal tract, where it
plays a protective role by removing endogenous and exoge-
nous xenobiotics, i.e. bacterial toxins from cells to the extra-
cellular environment. Any changes in the ABCG2 gene, such
as SNPs or in gene mRNA expression, may influence the
protein level and/or its function. That may lead to a loss of
its protective function and, thus, increase the risk of peptic
ulcer development. Imai et al. showed that the occurrence of
allele A of the SNP at position C421Amay be associated with
a lower expression of the protein in comparison to wild-type C
of this polymorphism. It was suggested that the substitution of
glutamine by lysine on position 141, as a consequence of the
studied SNP, may lead to the increased susceptibility to deg-
radation of the protein. This is a consequence of the fact that
lysine and glutamine have different electronic charges, which
might alter the tertiary structure of protein (Imai et al. 2002).
So far, to the best of our knowledge, participation of the
ABCG2 gene polymorphism at position C421A and mRNA
expression in the peptic ulcer development has not been in-
vestigated. All genotypes in the peptic ulcer patients and
healthy individuals were in accordance with the Hardy–
Weinberg rule, which proves their representativeness of the
studied population (Table 1). In this research, the dominant
genotype was homozygous CC, which is similar to the results
in European Caucasian (de Jong et al. 2004), non-Hispanic
Caucasian (Gardner et al. 2008), Hungarian (Fehér et al.
2013) and Sub-African populations (de Jong et al. 2004),
but which was different in Han Chinese (Hu et al. 2007),
Korean (Kim et al. 2010) and Japan (Imai et al. 2002) popu-
lations. Contrary to our results, the incidence of genotype CC
in those studies was lower but homozygous AA occurred with
a greater frequency than in Caucasian and African
populations.
Through the comparison of genotyping results between
peptic ulcer patients and healthy individuals, the impact of
the investigated polymorphism on peptic ulcer development
was estimated. No statistically significant differences for this
polymorphism were found (Table 1). Therefore, it can be as-
sumed that the studied polymorphism is not associated with an
increased risk of developing peptic ulcer disease. However,
the results may confirm a protective role of ABCG2, which
may be associated with the presence of the CC genotype of the
SNP on position C421A. This genotype is connected with a
higher expression and transport activity of protein (Morisaki
et al. 2005), which, in turn, will lead to a greater elimination of
toxins/xenobiotics from gastric mucosa cells. Sparreboom
et al. (2005), in a study on the cell line HEK293, showed that
allele C of C421A was responsible for the overexpression of
ABCG2 and decreased cell accumulation of topotecan. On the
other hand, HEK293 cells with the allele A variant of the
studied SNP showed an increase in the intracellular accumu-
lation of topotecan.
Our hypothesis may be confirmed by the results of the
research presented by Gardner at el. (2008), who also
Table 4 Relative ABCG2 expression level according to gender, age,
presence and intensity of H. pylori infection
Feature n Relative ABCG2 expression level p-Value
Mean Min. Max. SD
Gender 0.4957a
Female 21 −0.05 −1.28 1.75 0.82
Male 17 −0.22 −1.64 1.28 0.72
Age
<60 years 17 −0.22 −1.28 0.75 0.63 0.5329a
>60 years 21 −0.06 −1.64 1.75 0.88
H. pylori infection
Absent 26 −0.22 −1.64 1.03 0.68 0.2864a
Present 12 0.07 −1.19 1.75 0.95
H. pylori infection intensity




Medium 3 0.08 −0.86 0.75 0.69
High 4 1.10 0.27 1.75 0.76
a Student’s t-test
b ANOVA
Tukey’s HSD test: c low vs. medium, dmedium vs. high, e low vs. high
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demonstrated no statistical significance between polymor-
phism at position C421A and risk of prostate cancer
development, but a higher incidence of the CC genotype
was associated with increased survival in patients with this
cancer. Zhou et al. (2014) showed that the occurrence of ge-
notype AA and allele A was associated with higher risk of
gout development in the male Han Chinese population.
This is the first report concerning ABCG2 expression in the
gastric mucosa of peptic ulcer patients. We found expression
of the gene in 63.3 % of analysed samples. Previously,
ABCG2 protein was investigated by immunohistochemistry
in selected human tissues. Prominent ABCG2 immunostain-
ing was stated in the gastrointestinal tract, with strong apical
staining of the epithelium of the small intestine and colon, but
no staining in the stomach epithelium was found. ABCG2/
PBGD mRNA expression ratios in this tissue measured by
qualitative RT-PCR was relatively low (Maliepaard et al.
2001). In the presented research, in samples positive for
ABCG2 expression, the level of expression differed highly
among cases. As ABCG2 protein was not stated by others
(Maliepaard et al. 2001) in the epithelium of the stomach,
the observed expression of ABCG2 could derive from the
capillaries endothelial cells, where expression of the protein
was shown (Diestra et al. 2002; Maliepaard et al. 2001).
ABCG2 expression is regulated by hormones. The ABCG2
promoter estrogen and progesterone response elements were
described. It has been shown (Ee et al. 2004; Mao 2008) that
these hormones increase the level of mRNA or BCRP, which
could suggest that some gender-dependent differences in the
ABCG2 expression level exist. However, we found no associ-
ation between gender and the presence of ABCG2 expression.
Similarly, no connection between gender and level of the
ABCG2 expression was stated. It remains in agreement with
research results obtained by Gutmann et al. (2005), who
showed that the expression of ABCG2 mRNAwas not signif-
icantly different between males and females, in neither the
duodenum and the terminal ileum nor in the different colonic
segments of the human gastrointestinal tract.
Recently, we have shown that the expression level of an-
other gene belonging to the ABC transporter superfamily,
namely ABCB1, is associated with age in peptic ulcer patients
(Jażdżyk et al. 2014). ABCB1 expression was higher in older
patients. There is also some evidence that ABCG2 could ex-
hibit a differential level of the expression depending on age.
Kawase et al. (2015) stated that the mRNA level of ABCG2
decreased with age in the liver of female rats (but not in
males). On the other hand, when the expression of ABCG2
by liquid chromatography coupled with tandem mass spec-
trometry in the human liver was investigated, the expression
was not associated with age, gender or mRNA expression
(Prasad et al. 2013). In the presented study, neither the pres-
ence nor the level of the expression ofABCG2were connected
with age and gender. Considering this and the previously
published contradictory findings, the existence of a link
between ABCG2 expression and age and gender remains
unanswered.
Pet rovic et a l . (2015) examined the effect of
chorioamnionitis, a bacterial intra-amniotic infection, on the
expression of the ABCG2 gene and related protein in human
placenta. Expression of both the gene and the protein was
downregulated in placentas from women with infection rela-
tive to healthy controls. In our study, the impact of H. pylori
infection on mRNA expression of the transporter in gastric
mucosa was analysed. Neither the presence nor the level of
Fig. 1 Relative expression level
of ABCG2 according to the
Helicobacter pylori infection
intensity
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expression of ABCG2 were connected with the presence of
H. pylori infection in the investigated peptic ulcer patients.
However, when the subgroup of infected patients was
analysed, the presence of expression was stated to be signifi-
cantly more frequent in patients of medium or high intensity
of H. pylori infection in relation to those of low intensity of
infection. Moreover, it was discovered that the more intense
the infection, the higher the mean value of the expression. The
obtained results could suggest that H. pylori could potentiate
the expression of the investigated gene. In the above-
mentioned research, Petrovic et al. (2015) showed that, in
the placenta of infected woman, the ABCB1 expression level
correlates with the expression level of interleukin-6 (IL-6),
interleukin-1β (IL-1β) and tumour necrosis factor-α
(TNF-α), which could indicate the involvement of these cy-
tokines in expression regulation of the gene. Evseenko et al.
(2007) showed that the treatment of primary term trophoblasts
with TNF-α and IL-1β significantly decreased ABCG2 pro-
tein and mRNA expression, but IL-6 had no significant effect.
On the other hand, epidermal growth factor (EGF) and
insulin-like growth factor II significantly increased ABCG2
protein and mRNA expression. It could also be speculated
that ABCG2 expression in the mucosa of peptic ulcer patients
could be under an influence of inflammatory cytokine.
However, it should be confirmed using a histopathological
assessment of H. pylori density and inflammation degree in
a larger group of patients.
The aim of this study was to evaluate the participation of
polymorphism at position C421A and mRNA expression of
the ABCG2 gene in the development of peptic ulcer.
Conclusion
Based on these studies, it can be concluded that the ABCG2
gene has no connection with the development of peptic ulcers,
although Helicobacter pylori infection may lead to increased
expression levels of ABCG2 mRNA, because, with the more
intense infection with bacterium, a higher level of ABCG2
expression was observed.
On the other hand, in this study, because of the small
amounts of biopsies material studied, patients with peptic ul-
cer were divided into two investigated groups and the analyses
of C421A single nucleotide polymorphism (SNP) and mRNA
expression of ABCG2 were performed independently of each
other. However, as the literature suggests, ABCG2 expression
is largely determined by genetic polymorphisms; thus, it
would be beneficial to compare, in the future, the results of
genotyping and expression data in the same group of patients
with peptic ulcer.
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